CHEK1 and lung adenocarcinoma: Given that MYBL2 High patients have significantly poorer outcomes (Figure 2, Tables 1, 2), we explored the cytotoxic efficacy of small molecule CHK1 inhibitors in MYBL2 High lung adenocarcinoma cells.